EU Grants Conditional Approval for First Targeted pLGG Therapy

Ipsen has secured a conditional marketing authorization from the European Commission for Ojemda (tovorafenib), positioning the once-weekly oral RAF inhibitor as the first targeted therapy approved in the EU for relapsed or refractory pediatric low-grade glioma (pLGG) irrespective of BRAF alteration type. The decision, which extends across all 27 EU Member States plus Iceland, Liechtenstein, and Norway, arrives in a therapeutic area where fewer than 10% of new medicine approvals over the past five years have addressed pediatric diseases -- a structural gap that regulatory and industry stakeholders have long flagged as a patient safety concern. For QA and regulatory teams tracking conditional approval pathways under EU legislation, the authorization signals how pivotal Phase II data packages, when robustly constructed, can satisfy the European Medicines Agency's benefit-risk threshold ahead of full dataset maturity.

The conditional authorization covers patients aged 6 months and older harboring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have progressed after one or more prior systemic therapies. More than 800 children are diagnosed with BRAF-altered pLGG annually in the EU. Although classified as low-grade due to slow progression, the tumor carries substantial long-term morbidity, including loss of vision, speech difficulties, and motor dysfunction, with documented impact on education, independence, and quality of life. Prior standard-of-care pathways have involved invasive surgery, multiple chemotherapy lines, and radiotherapy, each carrying its own complication profile. Tovorafenib's once-weekly oral formulation -- available in both liquid and tablet form, administered with or without food -- represents a meaningful shift in administration burden for pediatric patients and their caregivers.

The approval package is anchored in data from the pivotal Phase II FIREFLY-1 study, which enrolled 137 children and young adults with relapsed or refractory BRAF-altered pLGG who had received at least one prior systemic therapy. Efficacy readouts under two established neuro-oncology assessment frameworks showed an overall response rate of 71% per RANO-HGG criteria and 53% per RAPNO-LGG criteria, with a clinical benefit rate of 77% and 58% respectively. Among responders assessed by RAPNO-LGG criteria, median time to response was 5.4 months and median duration of response reached 18.0 months. The safety profile was characterized predominantly by Grade 1 or 2 treatment-related adverse events; 9.5% of patients discontinued due to investigator-assessed tovorafenib-related events. Commonly reported TRAEs included hair color changes, elevated blood creatine phosphokinase, fatigue, anemia, vomiting, hypophosphataemia, headache, maculo-papular rash, pyrexia, growth retardation, and dry skin.

Regulatory and manufacturing context: Conditional marketing authorizations in the EU require post-authorization confirmatory data commitments, meaning Ipsen's pharmacovigilance and regulatory affairs functions will need to maintain robust post-market surveillance infrastructure aligned with ICH E2E and applicable GMP obligations for the commercial supply chain. Plant heads and quality leads supporting the tovorafenib supply network should anticipate heightened scrutiny on batch release documentation and deviation management as the product scales across a multi-country distribution footprint. Professor Francois Doz of Paris Descartes University and the SIREDO Oncology Centre at the Curie Institute has been cited in connection with the clinical program, reflecting the academic-industry collaboration underpinning the evidence base.

Sandra Silvestri, Executive Vice President and Chief Medical Officer at Ipsen, stated: "Today's approval is a meaningful step forward for these children, and their families, while reinforcing our commitment to addressing high unmet need. Now, our focus is on ensuring that eligible children across Europe can access this therapy as quickly as possible." For regulatory affairs leads monitoring rare pediatric drug development pathways, the FIREFLY-1 data package and the EC's conditional authorization decision will serve as a reference case for structuring future submissions in similarly underserved oncology indications.